| Literature DB >> 28336877 |
Ioana Turcu1, Irina Zarafu2, Marcela Popa3,4, Mariana Carmen Chifiriuc5,6, Coralia Bleotu7,8, Daniela Culita9, Corneliu Ghica10, Petre Ionita11,12.
Abstract
Water soluble gold nanoparticles protected by lipoic acid were obtained and further functionalized by standard coupling reaction with 1-naphtylamine, 4-aminoantipyrine, and 4'-aminobenzo-15-crown-5 ether. Derivatives of lipoic acid with 1-naphtylamine, 4-aminoantipyrine, and 4'-aminobenzo-15-crown-5 ether were also obtained and characterized. All these were tested for their antimicrobial activity, as well as for their influence on mammalian cell viability and cellular cycle. In all cases a decreased antimicrobial activity of the obtained bioactive nanoparticles was observed as compared with the organic compounds, proving that a possible inactivation of the bioactive groups could occur during functionalization. However, both the gold nanoparticles as well as the functionalized bioactive nanosystems proved to be biocompatible at concentrations lower than 50 µg/mL, as revealed by the cellular viability and cell cycle assay, demonstrating their potential for the development of novel antimicrobial agents.Entities:
Keywords: antimicrobial; cellular cycle; cytotoxicity; gold nanoparticles; lipoic acid; thioctic acid
Year: 2017 PMID: 28336877 PMCID: PMC5333028 DOI: 10.3390/nano7020043
Source DB: PubMed Journal: Nanomaterials (Basel) ISSN: 2079-4991 Impact factor: 5.076
Figure 1Synthesis of lipoic acid (LA) Au NPs (left) and their transmission electron microscopy (TEM) image (right). Scale bar 10 nm.
Figure 2Top: Functionalization of Au NPs (I) with 1-naphtylamine, 4-aminoantipyrine, and 4′-amino-benzo-crown-5, yielding samples II–IV; Bottom: TEM images of samples II, III, and IV, respectively (scale bar 10 nm).
Figure 3Synthesis of the compounds V–VII starting from LA.
Minimal inhibitory concentration (MIC) values of the tested compounds against the tested microbial strains.
| Sample | ||||||
|---|---|---|---|---|---|---|
| >1 | >1 | >1 | >1 | >1 | >1 | |
| >1 | >1 | >1 | >1 | 1 | >1 | |
| >1 | >1 | >1 | >1 | >1 | >1 | |
| >1 | >1 | >1 | >1 | >1 | >1 | |
| >1 | >1 | >1 | >1 | 0.25 | >1 | |
| >1 | 0.031 | 1 | >1 | 0.002 | >1 | |
| >1 | 0.004 | >1 | >1 | 1 | >1 |
Figure 4Viability (%) of HeLa cells after 24 h treatment with different concentrations of the obtained nanoparticles.
Figure 5Flow cytometry diagrams of the HeLa cells’ cycle analysis grown in the presence of the tested nanoparticles.